Governor Newsom Signs Legislation For Lower Prescription Drug Prices

Photo Source: Gage Skidmore 

Published: 


Building off Governor Newsom’s January proposal, SB 852 brings California one step closer to establishing its own generic drug label – lowering costs and increasing access to life-saving treatments 

Legislation advances the state’s ongoing work to take on the rising cost of prescription drugs and big drug companies 

SACRAMENTO – Governor Gavin Newsom today announced that he has signed legislation to bring down the cost of prescription drugs for taxpayers, employers and consumers. Earlier this year, Governor Newsom announced a first-in-the-nation plan to lower the cost of prescription drugs by creating Cal Rx – a state-sponsored generic drug label. SB 852 by Senator Richard Pan (D-Sacramento), brings that proposal one step closer to reality. Under the bill, the California Health and Human Services Agency (CHHS) will develop manufacturing partnerships to produce or distribute generic prescription drugs, making essential medications affordable and accessible to more patients. It would also inject much needed competition into markets that have driven up prices for consumers and help address critical drug shortages.

“The cost of health care is way too high. Our bill will help inject competition back into the generic drug marketplace – taking pricing power away from big pharmaceutical companies and returning it to consumers,” said Governor Newsom. “California is using our market power and our moral power to demand fairer prices for prescription drugs. I am proud to sign this legislation affirming our ground-breaking leadership in breaking down market barriers to affordable prescription drugs.”

“Prescription drugs don’t work if people cannot afford to take them. I thank the Governor for his leadership to assure Californians will be able to have access to a reliable supply of affordable generic medications. With the signing of SB 852, California leads the country again in pursuing innovative ideas to increase health care access and affordability, this time for prescription drugs,” said Senator Pan.

SB 852 advances the Governor’s proposal in January to leverage California’s purchasing power to increase generic drug manufacturing as one solution to the prescription drug affordability crisis. The state has already begun to identify potential target medications and develop a strategic plan to promote state-led generic drug purchasing and manufacturing. California is also transitioning all Medi-Cal pharmacy services from managed care to direct state payment in 2021, strengthening California’s ability to negotiate better prices with drug manufacturers.

From his first day in office, the Governor has made addressing prescription drug pricing – one of the largest drivers of rising health care costs – a top priority for the Administration. Moments after being sworn in, the Governor signed an executive order to foster the creation of the nation’s biggest single-purchaser system for prescription drugs, which will ultimately allow all Californians and private employers to sit together at the bargaining table across from big drug companies when negotiating prescription drug prices. Last year, the Governor signed legislation prohibiting pay-for-delay agreements between brand name and generic drug manufacturers by making them presumptively anti-competitive. These anti-competitive deals hurt consumers and increase drug company profits by blocking the development of generic drug competition.

Under SB 852, CHHS will target drugs for manufacture that could produce the biggest cost savings, and will submit a report to the Legislature by July 1, 2022 analyzing how its efforts have impacted competition, access and costs for those drugs.

For full text of the bill, visit: http://leginfo.legislature.ca.gov.


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>